ZEN-3694 is under clinical development by Zenith Epigenetics and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II drugs for T-Cell Lymphomas have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ZEN-3694’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ZEN-3694 overview
ZEN-3694 is under development for the treatment of metastatic castration-resistant prostate cancer, solid tumors such as epithelial ovarian cancer, lung cancer, unspecified B-cell lymphomas, T-cell lymphoma, pancreatic cancer, melanoma, NUT midline carcinoma, ovarian cancer, fallopian tube cancer, metastatic colorectal cancer and primary peritoneal carcinoma. The drug candidate is administered through oral route. The drug candidate acts by targeting BRD2, BRD3, BRD4 and BRDT. It was also under development for the treatment of triple negative breast cancer, acute myelocytic leukemia and colon cancer.
Zenith Epigenetics overview
Zenith Epigenetics, a subsidiary of Zenith Capital Corp, is a clinical-stage biotechnology company that focuses on the discovery and development of small molecules for the inhibition of BET bromodomains. The company’s lead product ZEN-3694 is a BET inhibitor intended for the treatment of solid tumors, including metastatic prostate cancer, breast cancer, ovarian cancer, and lung cancer. Its platform integrates structural biology, medicinal chemistry, and modeling with biochemical and cell-based assays. It collaborates with research institutes and biopharma companies to conduct clinical trials and research. The company has a presence in Canada and the US. Zenith Epigenetics is headquartered in Calgary, Alberta, Canada.
For a complete picture of ZEN-3694’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
